Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dorsey, E. R.
Right arrow Articles by Schwid, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dorsey, E. R.
Right arrow Articles by Schwid, S. R.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow All Clinical trials
Right arrow Multiple sclerosis
NEUROLOGY 2007;68:1524-1528
© 2007 American Academy of Neurology

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis

E. R. Dorsey, MD, MBA, J. P. Thompson, BA, K. Noyes, PhD, MPH, A. W. Dick, PhD, R. G. Holloway, MD, MPH and S. R. Schwid, MD

From Department of Neurology (E.R.D., R.G.H., S.R.S.) and Department of Community and Preventive Medicine (J.P.T., K.N., R.G.H.), University of Rochester Medical Center, Rochester, NY; and The RAND Corporation (A.W.D.), Pittsburgh, PA.

Address correspondence and reprint requests to Dr. Ray Dorsey, University of Rochester Medical Center, 1351 Mt. Hope Blvd., Suite 223, Rochester, NY 14620 ray.dorsey{at}ctcc.rochester.edu

Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

Received September 1, 2006. Accepted in final form December 22, 2006.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. A. Cox, G. Shi, H. Yin, B. P. Vistica, E. F. Wawrousek, C.-C. Chan, and I. Gery
Both Th1 and Th17 Are Immunopathogenic but Differ in Other Key Biological Activities
J. Immunol., June 1, 2008; 180(11): 7414 - 7422.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. M. Ransohoff
Natalizumab for Multiple Sclerosis
N. Engl. J. Med., June 21, 2007; 356(25): 2622 - 2629.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.